Immatics shares early bispecific data as it seeks to make its name beyond cell therapy

Immatics' early clinical data on TCR bispecifics IMA401 and IMA402, with promising response rates in solid tumor patients, signifies a significant advancement in potential treatment options. This development could lead to improved therapeutic strategies for challenging cancers, offering hope for better outcomes in clinical practice.